PMC9755882_01
Coronal reformatted PET image before and after treatment initiation. Figure 1 (left) shows two hypermetabolic liver lesions. Figure 2 (right) shows complete response of both lesions.
fonc-12-997346-g001.jpg
PMC9755882_01_fonc-12-997346-g001.jpg
f1
First imaging reevaluation was performed in June, 2021 using a CT-PET scan that showed hepatic and bone complete response ( Figures 1 ,  2 ).
Sagittal reformatted PET image before and after treatment initiation. Multiple foci of intense bone uptake are shown in figure 3 (left). Figure 4 (right) shows metabolic response of every lesion.
fonc-12-997346-g002.jpg
PMC9755882_01_fonc-12-997346-g002.jpg
f2
First imaging reevaluation was performed in June, 2021 using a CT-PET scan that showed hepatic and bone complete response ( Figures 1 ,  2 ).
Mutant allele frequency of BRAF V600E mutation in plasma during treatment.
fonc-12-997346-g003.jpg
PMC9755882_01_fonc-12-997346-g003.jpg
f3
Mutation assay (Biocartis ) ( Figure 3 ). Mutant allele frequency (MAF) of 16.9% was detected before start the dabrafenib/trametinib treatment.